My research over the years has given a Sales/Price ratio of 15 times for purchases of Biopharma products. The purchaser rarely wants to buy higher than 15 times. I’m not talking about a takeover, this is for the sale of the product Daybue to commercialise. If anyone wants to weigh in on this… please do.
My research over the years has given a Sales/Price ratio of 15...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.310(1.54%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.45 | $19.74 | $4.663M | 234.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 507 | $19.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.89 | 765 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |